Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Study ID
NCT06297226
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Arlocabtagene Autoleucel — BIOLOGICAL
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

Key Dates

Start date
Mar 21, 2024
Status verified
May 2026
Primary completion
Jun 30, 2027
Completion
Jun 30, 2032

Study Design

Enrollment
230 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arlocabtagene Autoleucel Cohort 1
  • Experimental: Arlocabtagene Autoleucel Cohort 2

Primary Outcome Measure

Cohort 1: Best overall response (BOR) of partial response (PR) or better [ Time Frame: Up to approximately 5 years ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (41)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35294-3300
Susan Bal, Site 0001
205-934-1908
Banner MD Anderson Cancer CenterGilbertArizona85234
Ambuga Badari, Site 0025
University of Arkansas for Medical SciencesLittle RockArkansas72205
Sharmilan Thanendrarajan, Site 0037
000-000-0000
UCLA Hematology/Oncology - Westwood (Building 200 Suite 214)Los AngelesCalifornia90095
Sarah Larson, Site 0028
310-829-5471
UCSF Helen Diller Medical Center at Parnassus HeightsSan FranciscoCalifornia94143
Anupama Kumar, Site 0018
415-514-0768
Colorado Blood Cancer InstituteDenverColorado80218
Tara Gregory, Site 0049
720-754-4800
Mayo Clinic in FloridaJacksonvilleFlorida32224
Vivek Roy, Site 0062
000-000-0000
Miami Cancer Institute at Baptist Health, Inc.MiamiFlorida33176
George Nahas, Site 0045
201-310-8558
Moffitt Cancer CenterTampaFlorida33612
Ciara Freeman, Site 0029
813-745-2475
Northside HospitalAtlantaGeorgia30342
Scott Solomon, Site 0004
404-255-1930
Winship Cancer Institute of Emory UniversityAtlantaGeorgia30322
Nisha Joseph, Site 0009
502-608-5503
Northwestern Memorial HospitalChicagoIllinois60611
Seema Singhal, Site 0005
312-505-1290
University of Chicago Medical CenterChicagoIllinois60637
Jennifer Cooperrider, Site 0056
University of IowaIowa CityIowa52242
Christopher Strouse, Site 0019
630-917-8956
The University of Kansas Cancer Center - WestwoodWestwoodKansas66205
Leyla Shune, Site 0016
913-588-6029
Norton Women's and Children's HospitalLouisvilleKentucky40207
Don Stevens, Site 0026
502-899-3366
Local Institution - 0065BaltimoreMaryland21218-
Dana-Farber Cancer InstituteBostonMassachusetts02215
Omar Nadeem, Site 0036
617-632-3000
Massachusetts General HospitalBostonMassachusetts02114
Diana Cirstea, Site 0039
617-724-4000
Mayo Clinic in Rochester, MinnesotaRochesterMinnesota55905
Taxiarchis Kourelis, Site 0033
855-776-0015
Washington University School of MedicineSt LouisMissouri63110
Michael Slade, Site 0010
314-454-8304
Rutgers Cancer Institute of New JerseyNew BrunswickNew Jersey08901
Mansi Shah, Site 0034
732-209-5479
Roswell Park Cancer InstituteBuffaloNew York14263
Ehsan Malek, Site 0046
216-286-4441
Icahn School of Medicine at Mount SinaiNew YorkNew York10029
Adriana Rossi, Site 0002
646-962-6500
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065
Sham Mailankody, Site 0003
646-608-3712
University of North Carolina Medical CenterChapel HillNorth Carolina27599-7305
Eben Lichtman, Site 0031
617-842-6051
Local Institution - 0067CharlotteNorth Carolina28204-
Oncology Hematology CareCincinnatiOhio45242
Kruti Patel, Site 0054
888-961-4156
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer CenterColumbusOhio43210
Srinivas Devarakonda, Site 0032
570-423-0522
Oregon Health and Science UniversityPortlandOregon97239
Amrita Desai, Site 0038
503-494-0896
Sidney Kimmel Cancer Center - Jefferson HealthPhiladelphiaPennsylvania19107
Usama Gergis, Site 0070
917-698-4310
Tennessee OncologyNashvilleTennessee37203
Jesus Berdeja, Site 0066
615-329-0570
Vanderbilt University Medical CenterNashvilleTennessee37232
Muhamed Baljevic, Site 0043
917-913-9166
Local Institution - 0069AustinTexas78704-
UT Southwestern Medical CenterDallasTexas75390
Larry Anderson, Site 0035
214-648-5906
University of Texas MD Anderson Cancer CenterHoustonTexas77030
Krina Patel, Site 0027
713-792-6662
Methodist HealthCare System of San Antonio Clinical Trials Office, Texas Transplant InstituteSan AntonioTexas78229
Paul Shaughnessy, Site 0055
210-670-2313
LDS HospitalSalt Lake CityUtah84143
Bradley Hunter, Site 0050
801-408-3729
Virginia Oncology AssociatesNorfolkVirginia23502
gary Simmons, Site 0068
757-461-7084
Fred Hutchinson Cancer CenterSeattleWashington98109
Rahul Banerjee, Site 0011
206-606-1453
University of Wisconsin Carbone Cancer Center - University HospitalMadisonWisconsin53792
Zhubin Gahvari, Site 0015
608-262-9317

Find similar trials in Birmingham, AL

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
University of Alabama at Birmingham· Birmingham, ALBanner MD Anderson Cancer Center· Gilbert, AZUniversity of Arkansas for Medical Sciences· Little Rock, ARUCLA Hematology/Oncology - Westwood (Building 200 Suite 214)· Los Angeles, CAUCSF Helen Diller Medical Center at Parnassus Heights· San Francisco, CAColorado Blood Cancer Institute· Denver, CO

Related Studies